# Glucose Transporter Regulation in Obesity and Diabetes

> **NIH NIH R56** · BETH ISRAEL DEACONESS MEDICAL CENTER · 2022 · $172,900

## Abstract

Enter the text here that is the new abstract information for your application. This section must be no longer than 30 lines of text.
Bridge Funding for DK43051– PI: Barbara B. Kahn, MD
Long-term Overall Goal: To determine the mechanisms by which reduction of ChREBP in adipocytes causes systemic insulin resistance and impaired glucose transport in adipocytes. 
Background: Carbohydrate Response Element Binding Protein (ChREBP) is the major transcription factor regulating de novo lipogenesis (DNL, fatty acid synthesis from glucose) in adipocytes. We showed that adipose-selective ChREBP KO (AdChREBP KO) causes systemic insulin resistance and impairs insulin-stimulated glucose transport in adipocytes. In humans, expression of ChREBP and genes regulating DNL in adipose tissue correlate highly with insulin sensitivity measured by clamp. 
Specific Aims for One Year: 
Specific Aim 1: To maintain lab staff
Specific Aim 2: To maintain mouse lines
Specific Aim 3: To generate additional preliminary data

## Key facts

- **NIH application ID:** 10553357
- **Project number:** 2R56DK043051-29
- **Recipient organization:** BETH ISRAEL DEACONESS MEDICAL CENTER
- **Principal Investigator:** BARBARA B. KAHN
- **Activity code:** R56 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $172,900
- **Award type:** 2
- **Project period:** 1992-02-01 → 2023-03-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10553357

## Citation

> US National Institutes of Health, RePORTER application 10553357, Glucose Transporter Regulation in Obesity and Diabetes (2R56DK043051-29). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10553357. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*